FDA Flags Serious GMP Violations at Simtra BioPharma Facility

In March 2026, the U.S. Food and Drug Administration issued a Warning Letter to Simtra BioPharma Solutions following an unannounced inspection of its Halle/Westphalia, Germany site in September 2025. The inspection revealed significant breaches of Current Good Manufacturing Practice (CGMP) under 21 CFR Parts 210 and 211, leading regulators to classify the company’s products as “adulterated.”

A major concern was inadequate control in aseptic manufacturing. Inspectors found insufficient segregation of production areas, increasing the risk of contamination and product mix-ups, particularly in lines using Restricted Access Barrier Systems (RABS) for sterile drug production.

Additional issues involved flawed cleaning and disinfection systems. Poor pipe design, including long “dead legs,” contributed to microbial growth. Between 2023 and 2025, 47 contamination events were recorded, with several exceeding acceptable limits. The FDA also highlighted repeated detection of Gram-negative microorganisms in critical ISO 5 areas, pointing to serious gaps in environmental monitoring and hygiene control.

The agency has requested comprehensive corrective actions, including system redesign and stronger root cause analysis. The case underscores the FDA’s strict oversight of aseptic manufacturing and the importance of robust quality systems.

01-04-2026